ScripsAmerica

SCRCQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About SCRCQ

ScripsAmerica, Inc. engages in the distribution of generic and over-the-counter (OTC) drugs to hospitals, nursing homes, government agencies, and retail. The company is headquartered in Clifton, New Jersey. The company went IPO on 2012-05-30. The firm's subsidiaries include Main Avenue Pharmacy Inc. (Main Avenue), DispenseDoc Inc. (DispenseDoc) and Pharmacy Administration, Inc. (Pharmacy Administration). The company also holds interests in P.I.M.D. International LLC (PIMD). Its operations consist of the sale and compounding of non-sterile topical and transdermal pain creams through Main Avenue; wholesale sales to independent pharmacies and other medical providers through PIMD; pharmacy dispensing services for individual doctors through DispenseDoc, and billing and administrative services through Pharmacy Administration. Main Avenue's prescription pain creams incorporate approximately eight active pharmaceutical ingredients for application on the skin and in localized areas. As of December 31, 2014, PIMD held licenses in over 20 states to receive, store and ship Schedule 3 through Schedule 5 formulary pharmaceuticals.

Employees
0
Headquarters
Clifton, New Jersey
Listed
May 30, 2012
Sector
Consumer Staples
Industry
Consumer Staples Distribution & Retail

Leadership

ScripsAmerica executives
NameTitleSince
Brian Ettinger—2011
Adam Brosius—2015
Jeffrey Andrews——
Pelligrino Certa——
Joseph Camardo——
Michael Imperiale——
William Lewis——
Andrius Pranskevicius——

Similar companies

Companies in the same industry as ScripsAmerica

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.